464 related articles for article (PubMed ID: 27890396)
41. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
[TBL] [Abstract][Full Text] [Related]
42. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease.
Giffard PM; Tong SYC; Holt DC; Ralph AP; Currie BJ
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007511. PubMed ID: 31269021
[TBL] [Abstract][Full Text] [Related]
43. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia.
Pandey M; Langshaw E; Hartas J; Lam A; Batzloff MR; Good MF
J Immunol; 2015 Jun; 194(12):5915-25. PubMed ID: 25980008
[TBL] [Abstract][Full Text] [Related]
44. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
45. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.
Brandt ER; Teh T; Relf WA; Hobb RI; Good MF
Infect Immun; 2000 Dec; 68(12):6587-94. PubMed ID: 11083769
[TBL] [Abstract][Full Text] [Related]
46. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology.
Hayman WA; Toth I; Flinn N; Scanlon M; Good MF
Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119
[TBL] [Abstract][Full Text] [Related]
47. Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.
Williamson DA; Smeesters PR; Steer AC; Morgan J; Davies M; Carter P; Upton A; Tong SY; Fraser J; Moreland NJ
BMC Infect Dis; 2016 Oct; 16(1):561. PubMed ID: 27733129
[TBL] [Abstract][Full Text] [Related]
48. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
[TBL] [Abstract][Full Text] [Related]
49. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
[TBL] [Abstract][Full Text] [Related]
50. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
51. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
Mansour NM; Abdelaziz SA
Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
[TBL] [Abstract][Full Text] [Related]
52. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.
Penfound TA; Chiang EY; Ahmed EA; Dale JB
Vaccine; 2010 Jul; 28(31):5017-22. PubMed ID: 20546830
[TBL] [Abstract][Full Text] [Related]
53. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage.
Engel ME; Muhamed B; Whitelaw AC; Musvosvi M; Mayosi BM; Dale JB
Pediatr Infect Dis J; 2014 Feb; 33(2):208-10. PubMed ID: 23934204
[TBL] [Abstract][Full Text] [Related]
54. Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
Nordström T; Pandey M; Calcutt A; Powell J; Phillips ZN; Yeung G; Giddam AK; Shi Y; Haselhorst T; von Itzstein M; Batzloff MR; Good MF
J Immunol; 2017 Oct; 199(8):2794-2802. PubMed ID: 28904125
[TBL] [Abstract][Full Text] [Related]
55. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
[TBL] [Abstract][Full Text] [Related]
56. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.
Maruggi G; Chiarot E; Giovani C; Buccato S; Bonacci S; Frigimelica E; Margarit I; Geall A; Bensi G; Maione D
Vaccine; 2017 Jan; 35(2):361-368. PubMed ID: 27939014
[TBL] [Abstract][Full Text] [Related]
57. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
[TBL] [Abstract][Full Text] [Related]
58. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
59. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
[TBL] [Abstract][Full Text] [Related]
60. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
